

Fax: 617.418.2290 | Email: client.services@foundationmedicine.com | Order Online: foundationmedicine.com/order
IF REQUIRED FIELDS ARE NOT PROVIDED, TESTING MAY BE DELAYED.

PATIENT INFORMATION

First Name _____ MI _____ Last Name _____ Medical Record # _____ DOB (MM/DD/YYYY) _____ Sex F M
 Address _____ City _____ State _____ Postal Code _____ Country _____ Primary Phone _____

PRIMARY CANCER DIAGNOSIS & STAGE/DISEASE STATUS AT TIME OF TESTING

Primary ICD-10 (C&D codes only) _____ Stage _____
 Prior/Current Targeted Therapies (optional) _____
 Patient has received transplant? Yes No

Diagnosis:
 Colorectal Carcinoma Melanoma
 Breast NSCLC Ovarian
 Prostate Other _____

Disease Status (select all that apply):
 Metastatic Recurrent
 Refractory Relapse
 None Progression

Attachments: Copy of recent pathology/cytology reports including (if available), CBC/differential, BMA differential, FAB classification. Test results from all other Molecular Diagnostic Assays by FISH, IHC, or other genetic assays, e.g., ER, PR, HER2, EGFR, KRAS, etc.

TREATING PHYSICIAN INFORMATION (Please provide best contact information for case follow-up)

Facility Name _____ Treating Physician (full legal name) _____
 Facility Address _____ City _____ State _____ Postal Code _____ Country _____
 Foundation Medicine Account # (optional) _____ Email _____ Phone _____ Fax _____
 Additional Physician to be Copied (optional) _____ Facility Name (optional) _____ Email (optional) _____ Fax (optional) _____

TEST MENU | Test/Laboratory Developed Test (LDT) Selection

Genomic Test	Description	Accepted Specimen Type	Genomic Test	Description	Accepted Specimen Type
<input type="radio"/> FoundationOne®CDx	FDA-approved companion diagnostic for solid tumors	FFPE Tissue	<input type="radio"/> FoundationOne®Heme	LDT RNA & DNA sequencing for heme malignancies, sarcomas or solid tumors	Peripheral Whole Blood, Bone Marrow Aspirate, FFPE Tissue, Extracted Nucleic Acid
<input type="radio"/> FoundationOne®Liquid CDx	FDA-approved companion diagnostic for solid tumors	Peripheral Whole Blood	<input type="checkbox"/> Specimen has or is undergoing other NGS testing		
<input type="checkbox"/> If specimen submitted is insufficient for analysis, use portfolio reflex option (see back for details)			<input type="radio"/> IHC Testing for PD-L1	If ordering multiple IHC tests, 4 additional slides are needed per clone ordered.	FFPE tissue
			<input type="checkbox"/> SP142 (atezolizumab)	<input type="checkbox"/> 22C3 (cemiplimab-rwlc, pembrolizumab)	<input type="checkbox"/> 28-8 (nivolumab)

SPECIMEN RETRIEVAL | Provide all information required per sample type

Submitting Pathologist Name _____ Pathology Lab Name _____ Email _____ Phone _____ Fax _____
 I am requesting a specific specimen I will let the pathologist choose the specimen I am providing FFPE block return address on back of form
 Date of Collection (MM/DD/YYYY) _____ Specimen ID _____ Site of Biopsy _____ Alternate Choice (optional) _____
 FFPE Tissue
 I will arrange for specimen shipment **Peripheral Whole Blood**
 Contact the pathology lab to obtain specimen I will arrange for specimen shipment **Bone Marrow Aspirate/Extracted Nucleic Acid**
 Mobile Phlebotomy requested (see guidelines on website) Ordering Facility responsible for shipment

BILLING INFORMATION | Select one of the three payment options and complete all fields indicated (Asterisk indicates Medicare requirement)

Insurance: * Medicare * ABN Attached (if required, see back) Medicare Advantage Other Plan Name _____
 Policy # _____ Group # _____ Prior Authorization # _____
 Self-Pay: Contact Name _____ Email _____ Phone _____
 Facility: Address _____ City _____ State _____ Postal Code _____ Country _____ Same as Treating Physician

*** Patient status at time of specimen collection:**
 Office (non-hospital) Outpatient
 Inpatient (requires Discharge Date below MM/DD/YYYY)
 _____ OR Not yet discharged

PHYSICIAN SIGNATURE AND CONSENT

My signature certifies that I have determined that the test(s) being ordered is medically necessary for the patient, certifies that the results of this test will inform the patient's ongoing treatment plan, and certifies that I am the patient's treating physician. I have explained to the patient the nature and purpose of the test(s) to be performed and have obtained informed consent, to the extent required under applicable law, to permit Foundation Medicine, or any laboratory with which Foundation Medicine has contracted, to (a) perform the test(s) specified herein, (b) analyze and report on other genetic information generated during the testing process or conduct additional analyses of the patient's sample for future diagnostic or monitoring use, (c) retain the test results and tissues, cells, and genetic material, including DNA and RNA information generated during the testing process, for an indefinite period for internal quality assurance/operations purposes, (d) remove information that directly identifies the patient from the test results, tissues, cells, and genetic material, including DNA and RNA information generated during the testing process, and use or disclose such information and materials for future unspecified research or other purposes, and (e) release the test results and related patient information to the patient's third-party payer as needed for reimbursement purposes.

Treating Physician Signature _____ Printed Name (Full legal name) _____ Date (MM/DD/YYYY) _____

FFPE BLOCK RETURN INFORMATION

FFPE Block Return Address

City State Postal Code Country

Email Phone Fax

OTHER INFORMATION

For information on ICD codes, visit this website:
<https://icd10cmttool.cdc.gov/>

Portfolio Reflex Option:

If the "Portfolio Reflex" checkbox is selected, we will proceed with the initial NGS test selected and if the specimen does not meet the criteria for successful testing, we will automatically reflex to the other test detailed below and procure a new specimen. The failed test is not billed, and the successful test will be billed according to our standard practices. Please see foundationmedicine.com/order for more information.

Additional Case Information (optional)

TECHNICAL INFORMATION

FOUNDATIONONE® CDx

FoundationOne®CDx is a qualitative next-generation sequencing based *in vitro* diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com

FOUNDATIONONE® LIQUID CDx

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based *in vitro* diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com

FOUNDATIONONE® HEME

FoundationOne®Heme is a laboratory developed test that combines DNA sequencing of 406 genes and RNA sequencing of 265 genes for patients with hematologic malignancies, sarcomas or solid tumors where RNA sequencing is desired. The test can be used by physicians to identify potential targeted therapy options, detect alterations in prognostic genes, and sub-classify sarcoma diagnoses. For more information on FoundationOne Heme, please see its Technical Specifications at www.foundationmedicine.com/heme

IHC Testing

Scoring and clone utilization for PD-L1 testing is based on FDA-approved indications. Refer to www.foundationmedicine.com/ihc for information.

MEDICARE COVERAGE SUMMARY (Foundation Medicine tests may be covered by Original Medicare¹ and Medicare Advantage²)

TEST	CONDITIONS FOR MEDICARE COVERAGE	PATIENT COVERAGE CRITERIA
FoundationOne®CDx	Covered ³ if all patient coverage criteria are met. ABN required for an Original Medicare beneficiary if they do not meet the patient coverage criteria or if person ordering the test is not a treating physician ⁴ .	i) Patient has been diagnosed with a solid malignant neoplasm; AND ii) Patient has either recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer (only requires one of these to be met); AND iii) Patient has not been previously tested with the same test using NGS for the same cancer genetic content ⁵ ; AND iv) Patient has decided to seek further cancer treatment (e.g., therapeutic chemotherapy)
FoundationOne®Liquid CDx		
FoundationOne®Heme	Covered ⁵ if all patient coverage criteria are met. ABN required for an Original Medicare beneficiary if they do not meet the patient coverage criteria or if person ordering the test is not a treating physician ⁴ .	i) Patient has been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN); OR ii) Patient has a suspected myeloid malignancy with an undefined cytopenia for greater than 4 months, and other possible causes have been reasonably excluded AND (both criteria iii and iv below) iii) Patient has not previously received or is not currently receiving NGS testing on the specimen for which the test is currently being ordered iv) Patient has not been tested with the same test for the same genetic content ⁶

References

- Medicare administered by federal government.
- Medicare administered by private insurers.
- Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R - reference appendix B)
- A "treating physician" is a physician, as defined in §1861(r) of the Social Security Act, who furnishes a consultation or treats a beneficiary for a specific medical problem, and who uses the results of a diagnostic test in the management of the beneficiary's specific medical problem. More information is available at <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R80BP.pdf>.
- MolDx Local Coverage Determination (LCD): Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38047)
- Repeat testing (FoundationOne®CDx, FoundationOne®Liquid CDx, or FoundationOne®Heme) after disease progression (i.e., there is evidence of a new malignant growth despite response to a prior targeted therapy) or for additional primary cancer diagnosis may be covered under the NCD for qualifying Medicare beneficiaries.